Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elemene plus EGFR TKI versus EGFR TKI alone in EGFR-mutant lung adenocarcinoma
ChiCTR-IPR-17012912Phase 4Recruiting
- Sponsor
- Aichi Cancer Center
- Start
- Oct 2017
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Elemene in Non-small cell lung cancer adenocarcinoma (NSCLC) and bronchial carcinoma (2 arms), sponsored by Aichi Cancer Center. Primary endpoints: Objective remission rate and Progression-free survival. Started Oct 2017; status: recruiting.
02
Drugs
Elemene
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)bronchial carcinoma
Beyond the preview
Go deeper on ChiCTR-IPR-17012912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17012912.